Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

1278 - Clinical outcomes and dosing patterns of 2nd targeted therapy in metastatic renal carcinoma: a retrospective chart review in the EU


09 Oct 2016


Poster display


Daniel Heng


Annals of Oncology (2016) 27 (6): 266-295. 10.1093/annonc/mdw373


D. Heng1, J. Park2, J.E. Signorovitch3, H. Yang3, J. Song4, J. Weiss5, L. Dezzani2, T.B. Powles6

Author affiliations

  • 1 Medical Oncology, Tom Baker Cancer Centre, T2N 4N2 - Calgary/CA
  • 2 Novartis Oncology, Novartis Pharmaceuticals Corporation, 07932 - East Hanover/US
  • 3 Health Economics And Outcomes Research, Analysis Group, 02199 - Boston/US
  • 4 Health Economics And Outcomes Research, Analysis Group, 90071 - Los Angeles/US
  • 5 Life Sciences, Navigant, EC2V 5HA - London/GB
  • 6 Medical Oncology, Royal Free Hospital School of Medicine, NW3 2QG - London/GB


Abstract 1278


This study evaluates the real-world outcomes and dosing patterns of metastatic renal cell carcinoma (mRCC) patients treated with everolimus (EVE), axitinib (AXI), and sorafenib (SOR), and as 2nd targeted therapy in Europe. We expanded the study to include patients from an additional country and updated the results presented at ASCO GU 2016 (#558).


Oncologists and urologists in the UK, Germany, France, and the Netherlands reviewed charts of adult mRCC patients who experienced disease progression on 1st targeted therapy with sunitinib or pazopanib and initiated 2nd targeted therapy with EVE, AXI, or SOR between 10/2012 and 6/2013. Overall survival (OS) and progression-free survival (PFS) and from the initiation of 2nd targeted therapies were evaluated using Kaplan-Meier analyses, and compared across cohorts using multivariable Cox proportional hazards models. Proportions of patients with dose adjustments and dose intensities relative to the recommended doses were also compared.


A total of 309 charts were reviewed, with 115, 96, and 98 mRCC patients receiving EVE, AXI, and SOR as 2nd targeted therapy, respectively. Mean age was 60.2 years and 66.7% were male. The majority of patients received sunitinib as 1st targeted therapy (79.3%) and the rest received pazopanib (20.7%). No statistically significant differences were observed in OS or PFS after adjusting for patient characteristics [AXI vs. EVE: hazard ratio (HR) (95% CI): 1.22 (0.77-1.94) and 1.26 (0.81-1.95); SOR vs. EVE: HR (95% CI): 1.25 (0.75-2.10) and 1.47 (0.95-2.28)]. A significantly greater proportion of AXI-treated patients had a dose increase (AXI: 13.2% vs. EVE: 0.9%, p 


In this retrospective study, no statistically significant differences in OS or PFS were observed among patients treated with EVE, AXI, and SOR. Rates of dose escalation and relative dose intensities were significantly higher among AXI-treated patients compared to EVE- or SOR-treated patients.

Clinical trial identification

Legal entity responsible for the study

Novartis Pharmaceuticals Corporation


Novartis Pharmaceuticals Corporation


J. Park, L. Dezzani: is an employee of Novartis Pharmaceuticals. J.E. Signorovitch, H. Yang, J. Song: is an employee of Analysis Group, which received research funding from Novartis Pharmaceuticals for this project. J. Weiss: is an employee of Navigant, which received research funding from Novartis Pharmaceuticals for this project. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings